Stroke genetics: testing a heart medicine's fit
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a quick genetic test can help choose the right antiplatelet medicine for people who have had a mild stroke or a high-risk mini-stroke (TIA). The goal is to see if this personalized approach is possible in a hospital setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 89 years old
- You had a mild ischemic stroke or a high-risk TIA
- You arrived at UAB main hospital within 66 hours of your last known well time
- You are not on blood thinners (anticoagulants) before your stroke
- You did not receive clot-busting medicine (IV tPA) or mechanical clot removal
- Your stroke is not caused by atrial fibrillation, valve disease, a known blood clotting disorder, or a large artery blockage of 50% or more
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a rapid genetic test to choose antiplatelet medication can improve outcomes for people who have had a stroke or mini-stroke. The test checks a gene that affects how your body processes a common antiplatelet drug, so your doctors can pick the safest and most effective medicine for you.
This trial compares using a genetic test to choose between two anti-clot medications (clopidogrel and ticagrelor) versus the usual approach of giving clopidogrel alone. It aims to see if personalized treatment can better prevent strokes in people with narrowed brain arteries.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This study tests whether using a genetic test to choose your blood thinner (clopidogrel or ticagrelor) can improve how well the medication works. You may qualify if you have stable heart disease or a recent heart attack and are scheduled for a stent procedure.
This study tests whether guiding antiplatelet medication with a blood test can help prevent another stroke or TIA. It looks at people who have had a mild stroke or high-risk TIA within the last 48 hours.
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
Hear when a new Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.